Triomics Secures $15 Million in Series A Funding to Streamline Cancer Clinical Trials Matching
In the landscape of cancer treatment, clinical trials stand as beacons of hope, offering potential breakthroughs and extended lifespans for patients. Yet, despite the multitude of trials conducted annually in the United States, only a small fraction of eligible patients—3% to 5%—actually enroll in these investigational treatments. Triomics, a pioneering AI startup, aims to revolutionize this process, promising to drastically reduce the time it takes for doctors to match patients with appropriate trials.